Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 10, pp 2564–2572 | Cite as

Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease

  • Alyce J. M. Anderson
  • Laura K. Ferris
  • David G. Binion
  • Kenneth J. Smith
Original Article

Abstract

Background and Aims

Inflammatory bowel disease (IBD) patients are at increased risk of melanoma and non-melanoma skin cancers, and preventive care guidelines in IBD favor annual skin examinations. Here we estimate the cost-effectiveness of annual melanoma screening in IBD.

Methods

Melanoma screening was defined as receiving annual total body skin examinations starting at age 40 from a dermatologist. Screening was compared to US background total body skin examination rates performed by primary care practitioners. A Markov model was used to estimate intervention costs and effectiveness. Future costs and effectiveness were discounted at 3% per year over a lifetime horizon. Strategies were compared using a willingness-to-pay threshold of $100,000/quality-adjusted life year (QALY) gained.

Results

Annual melanoma screening cost an average of $1961 per patient, while no screening cost $81 per patient. Melanoma screening was more effective, gaining 9.2 QALYs per 1000 persons, at a cost of $203,400/QALY gained. Screening every other year was the preferred strategy, gaining 6.2 QALYs per 1000 persons and costing $143,959/QALY. One-way sensitivity analyses suggested the relative risk of melanoma in IBD, melanoma progression, and screening costs were most influential with clinically plausible variation, leading to scenarios costing < $100,000/QALY gained. Probabilistic sensitivity analyses suggested screening every other year was cost-effective in 17.4% of iterations.

Conclusions

Screening for melanoma in IBD patients was effective but expensive. Screening every other year was the most cost-effective strategy. Studies to identify IBD patients at the highest risk of developing melanoma may assist in targeting a prevention program in the most cost-effective manner.

Keywords

Cost-effectiveness Melanoma Skin cancer screening Inflammatory bowel disease 

Notes

Acknowledgments

Alyce Anderson is supported by an NIH training Grant (1TL1TR001858-01, PI: Kapoor). Kenneth J. Smith is supported by NIH (NCATS) TL1TR001858. Laura K. Ferris is supported by a National Cancer Institute Grant (5P50CA121973-08). Research reported in this publication was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR001858. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author’s contribution

Alyce Anderson, PhD, contributed to drafting of manuscript, figure design, table creation, data collection, model creation, and critical review of the manuscript. Laura K. Ferris, MD, PhD, contributed to collection of data, model review, and critical review of the manuscript. David G. Binion, MD, contributed to collection of data, model review, and critical review of the manuscript. Kenneth J. Smith, MD, MS, contributed to project supervision, assistance with model creation, model review, and critical review of the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

Laura Ferris serves as a consultant for DermTech, International. David Binion has served as a consultant for Janssen Biotech and Abbvie, and reports grant support from Takeda, Shire, Abbvie and Merck. Alyce Anderson and Kenneth Smith declare that they have no conflicts of interest to disclose.

References

  1. 1.
    Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;6:13.Google Scholar
  2. 2.
    Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–218.CrossRefGoogle Scholar
  3. 3.
    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–274.CrossRefGoogle Scholar
  4. 4.
    Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:e1.CrossRefGoogle Scholar
  5. 5.
    Abbas AM, Almukhtar RM, Loftus EV, Lichtenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014;109:1781–1793.CrossRefGoogle Scholar
  6. 6.
    U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;3:188–193.Google Scholar
  7. 7.
    US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for skin cancer: US preventive services task force recommendation statement. JAMA. 2016;26:429–435.CrossRefGoogle Scholar
  8. 8.
    Waldmann A, Nolte S, Weinstock MA, et al. Skin cancer screening participation and impact on melanoma incidence in Germany—an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012;28:970–974.CrossRefGoogle Scholar
  9. 9.
    Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;1:5395–5402.CrossRefGoogle Scholar
  10. 10.
    Makin JK, Warne CD, Dobbinson SJ, Wakefield MA, Hill DJ. Population and age-group trends in weekend sun protection and sunburn over two decades of the SunSmart programme in Melbourne, Australia. Br J Dermatol. 2013;168:154–161.CrossRefGoogle Scholar
  11. 11.
    Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258.CrossRefGoogle Scholar
  12. 12.
    Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015;24:141–149.CrossRefGoogle Scholar
  13. 13.
    U.S. Bureau of Labor Statistics: CPI Inflation Calculator [Internet]. Consumer Price Index Inflation Calculator [cited 2016 Oct 19]; Available from: http://www.bls.gov/data/inflation_calculator.htm.
  14. 14.
    Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;28:796–797.CrossRefGoogle Scholar
  15. 15.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;20:6199–6206.CrossRefGoogle Scholar
  16. 16.
    DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6:705–711.CrossRefGoogle Scholar
  17. 17.
    National Cancer Institute: Melanoma of the Skin—SEER Stat Fact Sheets [Internet]. Surveillance, Epidemiology, and End Results (SEER) Program 2014 [cited 2016 Mar 6]; Available from: http://seer.cancer.gov/statfacts/html/melan.html.
  18. 18.
    Arias E. United States life tables, 2008. Natl Vital Stat Rep. 2012;24:1–63.Google Scholar
  19. 19.
    Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–1904.CrossRefGoogle Scholar
  20. 20.
    Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007;143:21–28.CrossRefGoogle Scholar
  21. 21.
    Okafor PN, Stallwood CG, Nguyen L, et al. Cost-effectiveness of nonmelanoma skin cancer screening in Crohn’s disease patients. Inflamm Bowel Dis. 2013;19:2787–2795.CrossRefGoogle Scholar
  22. 22.
    Overview of the Medicare Physician Fee Schedule [cited 2017 May 7]; Available from: https://www.cms.gov/apps/physician-fee-schedule/overview.aspx.
  23. 23.
    Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–792.CrossRefGoogle Scholar
  24. 24.
    Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL. Prevalence and correlates of skin cancer screening among middle-aged and older white adults in the United States. Am J Med. 2010;123:439–445.CrossRefGoogle Scholar
  25. 25.
    Saraiya M, Hall HI, Thompson T, et al. Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys. Prev Med. 2004;39:308–314.CrossRefGoogle Scholar
  26. 26.
    LeBlanc WG, Vidal L, Kirsner RS, et al. Reported skin cancer screening of US adult workers. J Am Acad Dermatol. 2008;59:55–63.CrossRefGoogle Scholar
  27. 27.
    Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–6. Value Health. 2012;15:835–842.CrossRefGoogle Scholar
  28. 28.
    Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040–2059.CrossRefGoogle Scholar
  29. 29.
    Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–186.CrossRefGoogle Scholar
  30. 30.
    Regueiro MD, McAnallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The inflammatory bowel disease specialty medical home: a new model of patient-centered care. Inflamm Bowel Dis. 2016;22:1971–1980.CrossRefGoogle Scholar
  31. 31.
    Uscher-Pines L, Malsberger R, Burgette L, Mulcahy A, Mehrotra A. Effect of teledermatology on access to dermatology care among medicaid enrollees. JAMA Dermatol. 2016;1:905–912.CrossRefGoogle Scholar
  32. 32.
    Guy GP, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990–2011. Am J Prev Med. 2012;43:537–545.CrossRefGoogle Scholar
  33. 33.
    Tabibian A, Tabibian JH, Beckman LJ, Raffals LL, Papadakis KA, Kane SV. Predictors of health-related quality of life and adherence in Crohn’s disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015;60:1366–1374.CrossRefGoogle Scholar
  34. 34.
    Zelante A, De Giorgi A, Borgoni R, Trevisani L, Gallerani M. Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol. 2014;60:269–274.PubMedGoogle Scholar
  35. 35.
    Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany—results of a multicentre and longitudinal study. Eur J Cancer. 2015;51:653–667.CrossRefGoogle Scholar
  36. 36.
    Chen SC, Pennie ML, Kolm P, et al. Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med. 2006;21:678–682.CrossRefGoogle Scholar
  37. 37.
    Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol. 2007;143:488–494.CrossRefGoogle Scholar
  38. 38.
    Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630–641.CrossRefGoogle Scholar
  39. 39.
    Greenberg D, Schwartz D, Vardi H, et al. Health-Related Utility Weights in a Cohort of Real-World Crohn’s Disease Patients. J Crohns Colitis. 2015;9:1138–1145.CrossRefGoogle Scholar
  40. 40.
    King SM, Bonaccorsi P, Bendeck S, et al. Melanoma quality of life: pilot study using utility measurements. Arch Dermatol. 2011;147:353–354.CrossRefGoogle Scholar
  41. 41.
    Shahwan KT, Kimball AB. Should we leave the skin biopsies to the dermatologists? JAMA Dermatol. 2016;152:371–372.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of DermatologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Division of Gastroenterology, Hepatology and NutritionUniversity of Pittsburgh Medical CenterPittsburghUSA
  4. 4.Department of MedicineUniversity of PittsburghPittsburghUSA

Personalised recommendations